Bringing CAR T-Cell Therapy to the Community Setting
Social drivers of health such as geographic distance, travel burden, or limited availability at specialized patient centers bar many eligible patients from receiving first-line, potentially curative therapies, including chimeric antigen receptor (CAR) T-cell therapy. Community cancer centers in particular often struggle to offer CAR T, due to the extensive resources required to safely maintain a CAR T program: emergency department access, intensive care unit resources, and inpatient admission availability.
In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Andrew…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.